- Home
- SWVL vs RNXT Comparison
SWVL vs RNXT Comparison
Compare SWVL & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- RNXT
- Stock Information
- Founded
- SWVL 2017
- RNXT 2012
- Country
- SWVL United Arab Emirates
- RNXT United States
- Employees
- SWVL N/A
- RNXT N/A
- Industry
- SWVL Business Services
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- RNXT Health Care
- Exchange
- SWVL Nasdaq
- RNXT Nasdaq
- Market Cap
- SWVL 37.6M
- RNXT 44.6M
- IPO Year
- SWVL N/A
- RNXT 2021
- Fundamental
- Price
- SWVL $3.47
- RNXT $1.27
- Analyst Decision
- SWVL
- RNXT Strong Buy
- Analyst Count
- SWVL 0
- RNXT 2
- Target Price
- SWVL N/A
- RNXT $7.50
- AVG Volume (30 Days)
- SWVL 17.2K
- RNXT 579.5K
- Earning Date
- SWVL 09-08-2025
- RNXT 11-12-2025
- Dividend Yield
- SWVL N/A
- RNXT N/A
- EPS Growth
- SWVL N/A
- RNXT N/A
- EPS
- SWVL N/A
- RNXT N/A
- Revenue
- SWVL $19,329,423.00
- RNXT $662,000.00
- Revenue This Year
- SWVL N/A
- RNXT $2,988.37
- Revenue Next Year
- SWVL N/A
- RNXT $300.60
- P/E Ratio
- SWVL N/A
- RNXT N/A
- Revenue Growth
- SWVL N/A
- RNXT N/A
- 52 Week Low
- SWVL $2.40
- RNXT $0.75
- 52 Week High
- SWVL $7.50
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- SWVL 41.69
- RNXT 60.58
- Support Level
- SWVL $3.33
- RNXT $1.06
- Resistance Level
- SWVL $4.01
- RNXT $1.45
- Average True Range (ATR)
- SWVL 0.33
- RNXT 0.11
- MACD
- SWVL 0.02
- RNXT 0.03
- Stochastic Oscillator
- SWVL 34.94
- RNXT 67.27
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.